According to an exchange filing, Olesoft Trucera contains N-Palmitoyl Serinol, which stimulates the skin’s natural ceramide production, a potent blend of five ceramides to lock in moisture and support the skin barrier’s function, and dual oat-extract actives along with Niacinamide to provide anti-inflammatory benefits. Olesoft Trucera will be available on prescription.
Commenting on the launch, Dr Vikas Gupta, chief executive officer, Alkem, said, “Indian consumers are increasingly seeking advanced skincare regimens with products that are clinically validated and contain high-performance actives. Alkem is strengthening its presence in this space with differentiated, evidence-backed solutions that address patient needs. The launch of Olesoft Trucera reflects this approach, combining science and clinical insights to offer a meaningful option for long-term skin barrier repair and lasting protection against moisture loss. This is also part of Alkem’s broader strategy to focus on smart product selection in high-growth therapy areas.”
Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products.
The company’s consolidated net profit jumped 21.8% to Rs 664.26 crore in Q1 FY26 as compared with Rs 545.16 crore posted in Q1 FY25. Net sales rose 11.2% YoY to Rs 3,371.14 crore in the quarter ended 30 June 2025.
The scrip rose 0.79% to currently trade at Rs 5,391 on the BSE.